Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
Yanchao Yin, Yamin Shu, Junru Zhu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post‐marketing safety
Cheng Jiang, Jiancheng Qian, Xin Jiang, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 10
Rare skin adverse reactions induced by osimertinib: a case report and literature review
Ye Zhang, Mathew Ling, Min Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
Huiping Hu, Maochang Liu, Zhiwen Fu, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 1
Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis
Rebecca Preyra, Lujain Ez Eddin, Fatemeh Ahmadi, et al.
British Journal of Clinical Pharmacology (2025)
Open Access | Times Cited: 1
A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
Zhiwei Cui, Feiyan Cheng, Lihui Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib
Yiming Qi, Jing Li, Sisi Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018–2023
Jinger Lin, X.Y. Chen, Min Luo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
Thromboembolic Events Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of the US FDA Adverse Event Reporting System (FAERS) Database
Xiongwen Yang, Bo Ram Yang, Dan Li, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 3, pp. 199-207
Closed Access | Times Cited: 4
Real world pharmacovigilance assessment of drug related macular degeneration risks
Xiao Dong Chen, Shi‐Nan Wu, Shaopan Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
Wenwen Zhang, Yizhen Yin, Dan Yang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database
Yaqi Zeng, Zhe Chen, Y. Luo, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Safety profiles of sevoflurane in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
Chuang Yang, Baoguo Deng, Qiang Wen, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
What does real-world data reveal about cangrelor’s safety? An analysis of FDA adverse event reporting system (FAERS) database
Zhaojun Wang, Junhang Zhang, Donglei Shi, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Post-marketing safety surveillance of Amivantamab: a real world study based on the FDA adverse event reporting system
Xiang Fu, Dongqiang Zeng, Min Li, et al.
Expert Opinion on Drug Safety (2025), pp. 1-9
Closed Access
A real-world pharmacovigilance study and pharmacological analysis of sulfasalazine based on the FDA adverse event reporting system (FAERS) database
Dandan Guo, Bufu Tang, Peng Luo, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system
Dan Li, Yuan Zhang, Yuqi Wang, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database
Min Xu, Shanggang Xu, Xun Yi
BMC Immunology (2025) Vol. 26, Iss. 1
Open Access
A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
Yu Lin, Xinlei Zheng, Chen Yan, et al.
Heliyon (2024) Vol. 10, Iss. 6, pp. e27529-e27529
Open Access | Times Cited: 3
Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database
Jiancheng Qian, Shuohan Zhang, Cheng Jiang
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Drug-induced Parkinson-like events: a real-world study from 2004 to the first quarter of 2024 based on FAERS
Ke Wang, Junyan Chen, Mingquan Huang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study
Huan Zhang, Yunrui Song, F. Xia, et al.
BMC Pharmacology and Toxicology (2025) Vol. 26, Iss. 1
Open Access
Disproportionality analysis of drug-induced erectile dysfunction using FAERS database
Xiaona Tian, Dongqiang Luo, Wenxiang Zeng, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
Priyanka Sharma, Sheeba Varghese Gupta, Priyanka Bhatt, et al.
Canadian Journal of Physiology and Pharmacology (2024)
Closed Access | Times Cited: 3
Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database
Junlin Wu, Han-Biao Wu, Lili Chen, et al.
Expert Opinion on Drug Safety (2023) Vol. 23, Iss. 7, pp. 905-916
Closed Access | Times Cited: 7
Synergy of de-walled Ganoderma Lucidum spore powder (GLSP) on targeted therapy in advanced non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutant: protocol for a randomized, double-blind, placebo-controlled study
Tong-Tong Wu, Yuyi Chen, Zichun Yuan, et al.
BMC Complementary Medicine and Therapies (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top